Mimedx (MDXG) Net Income towards Common Stockholders (2011 - 2026)

Mimedx has disclosed Net Income towards Common Stockholders across 16 years of filings, most recently posting -$14.8 million for Q2 2026.

• In Q2 2026, Net Income towards Common Stockholders fell 254.29% year-over-year to -$14.8 million; the TTM figure through Jun 2026 stood at $6.2 million (down 80.48% YoY), while the FY2025 annual figure was $48.6 million, up 15.67% from the prior year.
• Net Income towards Common Stockholders came in at -$14.8 million for Q2 2026 at Mimedx, down from -$10.9 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $44.8 million in Q4 2023 to a low of -$14.8 million in Q2 2026.
• Average Net Income towards Common Stockholders over 5 years is $5.2 million, with a median of $7.5 million recorded in 2023.
• The largest YoY upside for Net Income towards Common Stockholders was 681.83% in 2022 against a maximum downside of 281.44% in 2022.
• Over 5 years, Net Income towards Common Stockholders stood at $8.1 million in 2022, then surged by 451.13% to $44.8 million in 2023, then sank by 83.41% to $7.4 million in 2024, then surged by 104.24% to $15.2 million in 2025, then tumbled by 197.69% to -$14.8 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$14.8 million in Q2 2026, -$10.9 million in Q1 2026, and $15.2 million in Q4 2025.